- Home
- URGN vs MMU Comparison
URGN vs MMU Comparison
Compare URGN & MMU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- MMU
- Stock Information
- Founded
- URGN 2004
- MMU 1992
- Country
- URGN United States
- MMU United States
- Employees
- URGN N/A
- MMU N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- MMU Investment Managers
- Sector
- URGN Health Care
- MMU Finance
- Exchange
- URGN Nasdaq
- MMU Nasdaq
- Market Cap
- URGN 547.1M
- MMU 562.0M
- IPO Year
- URGN 2017
- MMU N/A
- Fundamental
- Price
- URGN $11.33
- MMU $10.31
- Analyst Decision
- URGN Strong Buy
- MMU
- Analyst Count
- URGN 5
- MMU 0
- Target Price
- URGN $44.50
- MMU N/A
- AVG Volume (30 Days)
- URGN 351.4K
- MMU 170.7K
- Earning Date
- URGN 11-06-2024
- MMU 01-01-0001
- Dividend Yield
- URGN N/A
- MMU 4.92%
- EPS Growth
- URGN N/A
- MMU N/A
- EPS
- URGN N/A
- MMU N/A
- Revenue
- URGN $89,363,000.00
- MMU N/A
- Revenue This Year
- URGN $13.39
- MMU N/A
- Revenue Next Year
- URGN $45.06
- MMU N/A
- P/E Ratio
- URGN N/A
- MMU N/A
- Revenue Growth
- URGN 15.64
- MMU N/A
- 52 Week Low
- URGN $10.60
- MMU $8.60
- 52 Week High
- URGN $20.70
- MMU $10.45
- Technical
- Relative Strength Index (RSI)
- URGN 37.97
- MMU 33.56
- Support Level
- URGN $11.10
- MMU $10.53
- Resistance Level
- URGN $13.13
- MMU $10.64
- Average True Range (ATR)
- URGN 0.53
- MMU 0.10
- MACD
- URGN -0.10
- MMU -0.03
- Stochastic Oscillator
- URGN 12.15
- MMU 2.22
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About MMU Western Asset Managed Municipals Fund Inc.
Western Asset Managed Municipals Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is to maximize current income exempted from federal income tax as is consistent with the preservation of principal. It predominantly invests in long-term investment grade municipal debt securities issued by state and local governments, political subdivisions, agencies, and public authorities (municipal obligations). Under normal market conditions, a majority of its total assets are invested in municipal obligations rated investment grade at the time of investment.